| Serial Number | 79420148 |
| Word Mark | STAB |
| Filing Date | Friday, December 27, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Wednesday, February 4, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Biological preparations for use in cell cultures for medical purposes; preparations for detecting genetic predispositions for medical purposes; diagnostic reagents for medical use; chemical reagents for medical use; biological reagents for medical use; cells for medical use; living cells for medical use; antibodies for medical purposes; cell growth media for growing cells for medical or clinical use; cellular function activating agents for medical purposes; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; human and animal cells and related parts for medical use, namely, human cells and related parts for medical use, cell culture for medical use, viral vectors, for medical use, namely, pharmaceutical preparations containing viral vectors for the treatment or prevention of cancer and immune-related diseases; chemical reagents for medical use, namely, lentiviruses, lentivirus particles and lentivirus plasmids, for medical use; therapeutic preparations and substances for gene and cell therapy for medical" use, namely, pharmaceutical preparations for gene therapy and cell therapy for the treatment of cancer and immune-related diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes; lentiviral vectors, for medical use, namely, pharmaceutical preparations containing lentiviral vectors for gene and cell therapy for the treatment of cancer and immune-related diseases; adeno-associated viral vectors, adenoviral vectors and non-viral vectors for the delivery of genes to cells for medical use, namely, pharmaceutical preparations for gene therapy for the treatment of cancer and immune-related diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention of diseases of the immune system; all the aforesaid goods expressly excluding substances and preparations for veterinary use; medicines and pharmaceuticals based on messenger RNA (mRNA) for the treatment of cancer and immune-related diseases; pharmaceutical and medicinal preparations for use in the field of targeting messenger RNA (mRNA) and triggering its degradation for the treatment of cancer and immune-related diseases; mRNA-based therapeutic preparations and therapeutic agents for the prevention and treatment in vivo, ex vivo and in situ of oncological diseases or tumors; pharmaceutical preparations consisting of messenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for the treatment of cancer and immune-related diseases |
| Goods and Services | Licensing authority services in the field of cellular therapy, namely, patent licensing, trademark licensing; licensing authority services in the field of immunotherapeutics, namely, patent licensing, trademark licensing; licensing of technology, namely, patent licensing, trademark licensing; licensing of intellectual property |
| Goods and Services | Biological research; medical research services; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; gene therapy research; research and development in the field of microorganisms and cells; development of cell therapy products; product development in the field of immunotherapy; pharmaceutical drug development services in the field of cell therapy; pharmaceutical drug development services in the field of immunotherapy; development of gene-based medicines; design and development of medical technology in the field of cell therapy; design and development of medical technology in the field of immunotherapy; research and development of vaccines and medicines; consultancy relating to pharmaceutical research and development in the field of cell therapy; consultancy relating to pharmaceutical research and development in the field of immunotherapy; research and development services in the field of antibodies; research and development services in the field of gene expression systems; laboratory services relating to the production of monoclonal antibodies, namely, laboratory research services relating to pharmaceuticals and biotechnology; scientific services relating to the isolation and cultivation of human tissues and cells, namely, scientific research and scientific laboratory services; research and development services in the field of immunology; research and development services in the field of cell therapy; research and development services in the field of immunotherapy; research and development of mRNA drugs |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 28, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 28, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, March 28, 2025 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | STAB THERAPEUTICS, S.L.U. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | ES |
| Event Date | Event Description |
| Thursday, March 27, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, March 28, 2025 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Friday, March 28, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, March 28, 2025 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, June 10, 2025 | ASSIGNED TO EXAMINER |
| Sunday, June 15, 2025 | NON-FINAL ACTION WRITTEN |
| Monday, June 16, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, August 6, 2025 | REFUSAL PROCESSED BY MPU |
| Wednesday, August 6, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, August 23, 2025 | REFUSAL PROCESSED BY IB |
| Wednesday, February 4, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, February 4, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, February 4, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |